Johnson & Johnson (NYSE:JNJ) has reportedly raised its offer for Swiss biotech firm Actelion Pharmaceuticals (VTX:ATLN), pressuring the company to accept a takeover deal.
The companies have been in talks for nearly 2 months but so far have not reached a deal, according to Reuters.
The news outlet reported that Actelion wants J&J to become a major shareholder in a new entity, which would combine the Swiss group with some of J&J’s activities. But J&J is interested in a straightforward takeover.
Get the full story at our sister site, Drug Delivery Business News.
The post Report: J&J raises the stakes in Actelion pursuit appeared first on MassDevice.